OPEN ACCESS Freely available online

ISSN: 2167-7956
Journal of Biomolecular Research & Therapeutics

Opinion Article

CRISPR-Cas9 Mediated Genome Editing for Therapeutic Applications in Genetic Disorders

Henry Moreland*

Department of Genomics, University of California, California, United States of America

DESCRIPTION

CRISPR-Cas9 has revolutionized the field of genetic research and therapeutic applications since its discovery. This technology allows for precise, efficient, and cost-effective genome editing, offering unprecedented significant to treat genetic disorders. By leveraging the ability to modify specific DNA sequences, CRISPR-Cas9 capable of correcting genetic mutations at their source, thereby providing lasting solutions for many hereditary diseases.

Mechanism of CRISPR-Cas9

CRISPR-Cas9, which stands for Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9, is a naturally occurring system in bacteria used as a defense mechanism against viral infections. Scientists have adapted this system for genome editing by two major components: the Cas9 protein and a guide RNA (gRNA).

The Cas9 protein acts as molecular scissors that can cut DNA at specific locations, while the gRNA directs Cas9 to the target sequence by complementary base pairing. Once the DNA is cut, the cell's natural repair mechanisms are triggered. By introducing a desired DNA template along with the CRISPR components, researchers can prompt the cell to incorporate new genetic material during the repair process, thereby achieving precise gene modification.

Therapeutic applications in genetic disorders

The significance of CRISPR-Cas9 for therapeutic applications is vast, particularly for monogenic disorders-diseases caused by mutations in a single gene. Some of the most promising applications include:

Sickle cell disease and beta-thalassemia: These blood disorders are caused by mutations in the hemoglobin subunit beta (HBB gene), which encodes the beta-globin subunit of hemoglobin. CRISPR-Cas9 has been used to correct these mutations in hematopoietic stem cells. Edited cells are then transplanted back into the patient, leading to the production of healthy red blood cells and alleviating disease symptoms.

Cystic fibrosis: Caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR gene), cystic fibrosis results in the production of thick mucus that affects the lungs and digestive system. CRISPR-Cas9 can be used to correct CFTR mutations in patient-derived cells. Research is ongoing to develop effective delivery methods to target lung cells *in vivo*.

Duchenne Muscular Dystrophy (DMD): This severe muscle-wasting disorder is caused by mutations in the DMD gene. Researchers have successfully used CRISPR-Cas9 to restore the reading frame of the DMD gene in animal models, leading to the production of functional dystrophin protein and significant improvement in muscle function.

Inherited retinal diseases: CRISPR-Cas9 has shown in correcting mutations that cause blindness, such as Leber Congenital Amaurosis (LCA). By targeting specific retinal cells, researchers aim to restore vision in affected individuals.

Challenges and directions

While CRISPR-Cas9 offers significant therapeutics, several challenges remain before it can be widely adopted in clinical practice. One of the primary concerns is off-target effects, where unintended DNA sequences are modified, leading to harmful consequences. Advances in gRNA design and improvements in Cas9 specificity are ongoing to minimize these risks.

Efficient delivery of CRISPR components to target cells and tissues also poses a significant challenge. Various delivery methods, including viral vectors, lipid nanoparticles, and electroporation, are being explored and optimized to enhance the safety and efficacy of genome editing.

Correspondence to: Henry Moreland, Department of Genomics, University of California, California, United States of America, E-mail: moreland@gmail.com

Received: 03-Jun-2024, Manuscript No. BOM-24-26364; **Editor assigned:** 05-Jun-2024, Pre QC No. BOM-24-26364 (PQ); **Reviewed:** 19-Jun-2024, QC No. BOM-24-26364; **Revised:** 26-Jun-2024, Manuscript No. BOM-24-26364 (R); **Published:** 03-Jul-2024, DOI: 10.35248/2167-7956.24.13.385

Citation: Moreland H (2024) CRISPR-Cas9 Mediated Genome Editing for Therapeutic Applications in Genetic Disorders. J Biomol Res. 13:385.

Copyright: © 2024 Moreland H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CONCLUSION

CRISPR-Cas9 mediated genome editing represents a transformative approach to treating genetic disorders. Despite the challenges that need to be addressed, ongoing research and technological advancements are lead for clinical applications. The prospective of CRISPR-Cas9 in therapeutic settings are capable for revolutionizing the treatment of genetic diseases, ultimately improving the lives of countless individuals worldwide.